This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CAR-Treg Program (TxCell/UBC)
Drug Names(s): CAR-Treg Program (TxCell/UBC)
Description: TxCell and the University of British Columbia are developing a CAR-Treg-based cellular immunotherapy for the prevention of graft rejection in the context of solid organ transplantation (SOT).
TxCell and University of British Columbia
In October 2016, TxCell announced the signature of a strategic R&D collaboration agreement with the University of British Columbia (UBC) in Vancouver, Canada. This collaboration agreement covers the development of a CAR-Treg-based cellular immunotherapy for the prevention of graft rejection in the context of Solid Organ Transplantation (SOT). Activities relating to this program will be primarily conducted in the UBC laboratories. UBC will conduct non-clinical pharmacology studies with CAR-Treg cells with the aim of initiating a first-in-man study in transplantation patients as soon as possible. The Company aims to launch a first-in-man clinical study with a first CAR-Treg in 2018.
Whilst the UBC team is focused on product development activities, it will in parallel perform research activities in the CAR-Treg field with the aim of optimizing and broadening the new product platform for transplantation. TxCell has an exclusive...See full deal structure in Biomedtracker
CAR-Treg Program (TxCell/UBC) News
Additional information available to subscribers only: